OncoBeta Announces Approval and ARTG Listing of Rhenium-SCT (Rhenium-188 paste) in Australia for the treatment of skin cancer lesions and skin tumors

Garching n. Munich, Germany, (December 18th, 2020) – OncoBeta® GmbH and their subsidiary OncoBeta Therapeutics Pty Ltd. Australia a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanoma Skin Cancers (NMSCs), announced today that the Rhenium-SCT (Rhenium-188 paste) has been registered on the Australian Register of Therapeutic Goods (ARTG), which is the formal requirement for supply and marketing of the medical device. This advanced radionuclide therapy technology offers a non-invasive, single session, painless treatment with little to no scarring for patients suffering from Basal Cell – and Squamous Cell Carcinomas (BCCs and SCCs).

The global incidence of non-melanoma skin cancers has drastically increased over the past few decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases
reported globally each year. Australia having one of the highest incidence rates in the world. According to the Australian Institute of Health and Welfare (AIHW) Non-melanoma skin cancer (NMSC) is the most common
cancer diagnosed in Australia, with over 400,000 new cases per year.

“The approval of the Rhenium-SCT in Australia is a great step forward for patients wanting a new non-invasive and painless treatment option for Non-Melanoma Skin cancer.” said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH, “We are committed to bringing back quality of life to skin cancer sufferers.”

Nicholas H. Vetter, Chief Operating Officer of OncoBeta said: “after receiving the TGA approval we will now set up local production to make the Rhenium-SCT even more accessible to clinics, physicians and their patients throughout Australia.”